Contrasting SAB Biotherapeutics (NASDAQ:SABS) & Kiromic BioPharma (NASDAQ:KRBP)

Kiromic BioPharma (NASDAQ:KRBP) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Profitability

This table compares Kiromic BioPharma and SAB Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiromic BioPharma	N/A	N/A	-277.46%
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%

Analyst Ratings

This is a summary of recent ratings for Kiromic BioPharma and SAB Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiromic BioPharma	0	0	0	0	0.00
SAB Biotherapeutics	0	0	5	0	3.00

SAB Biotherapeutics has a consensus price target of $12.40, indicating a potential upside of 675.00%. Given SAB Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Kiromic BioPharma.

Insider and Institutional Ownership

10.9% of Kiromic BioPharma shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 20.6% of Kiromic BioPharma shares are owned by insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Kiromic BioPharma and SAB Biotherapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiromic BioPharma	N/A	N/A	-$26.90 million	($3.50)	-0.06
SAB Biotherapeutics	$2.24 million	6.59	-$42.19 million	N/A	N/A

Kiromic BioPharma has higher earnings, but lower revenue than SAB Biotherapeutics.

Volatility and Risk

Kiromic BioPharma has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

Summary

SAB Biotherapeutics beats Kiromic BioPharma on 6 of the 11 factors compared between the two stocks.

About Kiromic BioPharma

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.